Reading GRDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRDX free→Reading GRDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRDX free→QuarterlyIQ Insights · GRDX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2025, GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) (the “Company”) entered into a Revolving Loan Agreement dated January 27, 2025 (the “Revolving Loan Agreement”), with 1396974 BC Ltd. (the “Lender”) pursuant to which the Lender agreed to make loans to the Company. Under the Revolving Loan Agreement, the outstandi…
Entry Into a Material Definitive Agreement $2.54 million Financing On May 8, 2026, May 11, 2026 and May 12, 2026, GridAI Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company agreed to sell to the Purchasers in private placements an aggregate of (i) 74,000 shares of common stock, (ii) pre-funded warrants…
Unregistered Sales of Equity Securities. The disclosure under
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 22, 2026, GridAI Technologies Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the filing of periodic financial reports requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5250(c)(1), because the Company has no…
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2025, GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) (the “Company”) entered into a Revolving Loan Agreement dated January 27, 2025 (the “Revolving Loan Agreement”), with 1396974 BC Ltd. (the “Lender”) pursuant to which the Lend…
Completion of Acquisition or Disposition of Assets. As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 25, 2025, GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) (the “Company”) entered into a Rescission Agreement (the “Rescission Agreement”) by and among the Company, ImmunogenX, LLC (“Immuno LLC”) and each of the individuals or entities (each a “Shareholder” and collectively, the “Shareholders”) who are the former s…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2025, GridAI Technologies Corp. (the “Company”) had appointed Mr. Jason D. Sawyer as Interim Chief Executive Officer of the Company. Subsequently, as previously disclosed on the Current Report on Form 8-K filed with the Securi…
Entry into a Material Definitive Agreement. The information set forth below under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Mr. Eric Corbett as a director of the Company: On November 28, 2025, Mr. Eric Corbett notified the Company of his resignation as a director of GridAI Technologies Corp. (f/k/a Entero Therapeutics, Inc.) (the “Company”). Mr. Corbett’s resignation was a result of disagreements with members of the Company’s management and Board of Direc…
Entry into a Material Definitive Agreement. The information set forth below under
Entry Into a Material Definitive Agreement On October 17, 2025, Entero Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an investor (“Investor”), pursuant to which the Company may sell to the Investor in a private placement (“Offering”) up to $5,000,000 in gross proceeds: (i) Promissory Notes (“Notes”) and (ii) a common stock purchase warrant to purchase up to an aggregate of 1,520,000 shares of common stock (the “Warrant,” and th…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Unregistered Sales of Equity Securities. The information set forth under
Entry Into a Material Definitive Agreement The information set forth in
Completion of Acquisition or Disposition of Assets Share Exchange Agreement On September 30, 2025, the Company entered into and consummated a share exchange agreement (“Share Exchange Agreement”) with GridAI Corp, a Nevada corporation (“GridAI”), and the stockholders of all of the issued and outstanding shares of GridAI (such shares, the “Shares,” and the stockholders, collectively, the “Sellers,” and, the Sellers, together with the Company and GridAI, the “Parties”). Pursuant to the Share Ex…
Entry Into a Material Definitive Agreement The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Entry into Consulting Agreement for appointment of Jason D. Sawyer as CEO As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2025, the Company had appointed Mr. Jason D. Sawyer as Interim Chief Executive Officer of the Company. Subsequently, on September 8, 2025, the Company e…
Termination of a Material Definitive Agreement The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Termination of Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board On September 3, 2025, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”) terminated Richard Joel Paolone as Interim Chief Executive Officer of the Company and Chairman of the Board, without cause, effective immediately. Mr…
Material Modification to Rights of Security Holders. To the extent required by
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Directors to the Board of Directors In connection with the closing of the transactions contemplated by the Purchase Agreement, on August 9, 2025, the Board of Directors of the Company approved the appointment of Geordan Pursglove and Jason Sawyer to serve as members of the Board of Directors of the Company, effective as of August 11,…
Entry Into a Material Definitive Agreement On August 9, 2025, Entero Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company will sell to the Purchasers in a private placement an aggregate of (i) pre-funded warrants to purchase up to an aggregate of 4,878,841 shares of common stock (the “Pre-Funded Warrants…
Unregistered Sales of Equity Securities. The disclosure under
Other Events. Press Release On August 11, 2025, the Company issued a press release regarding the pricing of the private placement. A copy of the press release is attached as Exhibit 99.1 hereto.
Entry Into a Material Definitive Agreement Amendment to Rescission Agreement As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 25, 2025, Entero Therapeutics, Inc. (the “Company”) entered into a Rescission Agreement (the “Rescission Agreement”) by and among the Company, ImmunogenX, LLC (“Immuno LLC”) and each of the individuals or entities (each a “Shareholder” and collectively, the “Shareholders”) who are the former shareholde…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.